Drug interactions
Dantrolene + Lorlatinib
Severity: Minor
Dantrolene and Lorlatinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib is a CYP3A4 inducer and dantrolene is metabolised partly by CYP3A4, so dantrolene exposure may fall. The clinical significance has not been established and a loss of muscle relaxant effect is the main concern.
What this interaction means in plain words
Dantrolene and Lorlatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Dantrolene belongs to Musculoskeletal; Lorlatinib belongs to Oncology.
Why it happens
Lorlatinib induction of CYP3A4 may increase dantrolene metabolism.
What to do
Monitor for reduced dantrolene efficacy and adjust the dose to clinical response. Monitor liver function as usual during dantrolene therapy.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dantrolene and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Dantrolene
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Frequently asked questions
Can I take Dantrolene with Lorlatinib?
MediHelp rates the interaction as minor. Dantrolene and Lorlatinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Lorlatinib is a CYP3A4 inducer and dantrolene is metabolised partly by CYP3A4, so dantrolene exposure may fall. The clinical significance has not been established and a loss of muscle relaxant effect is the main concern.
How serious is the interaction between Dantrolene and Lorlatinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for reduced dantrolene efficacy and adjust the dose to clinical response. Monitor liver function as usual during dantrolene therapy.
What other medicines interact with Dantrolene?
MediHelp also lists interactions of Dantrolene with, for example, Benzhydrocodone / acetaminophen, Buprenorphine long-acting, Buprenorphine subdermal implant. The full list is on the Dantrolene page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
